19 de agosto de 2009 / 4:44 / en 8 años

Glenmark shares slide 17.4 pct on lung drug failure

MUMBAI, Aug 19 (Reuters) - Shares in Indian drugmaker Glenmark Pharmaceuticals (GLEN.BO) fell as much as 17.4 percent on Wednesday to their lowest in more than a month after the company and partner Forest Laboratories FRX.N said their lung drug failed in mid-stage trial. [ID:nSP458535]

At 0437 GMT, the company’s shares were down 9.4 percent at 237.05 rupees, after falling to as low as 216 rupees.

The 30-share BSE index .BSESN was up 0.2 percent. (Reporting by Pratish Narayanan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below